PAR 5.81% 20.3¢ paradigm biopharmaceuticals limited..

PAR Investor Meeting - Questions from HC, page-58

  1. 2,143 Posts.
    lightbulb Created with Sketch. 576
    This worked out well.

    No clarity on peer review, patents, TGA Provisional Approval, lack of public KOL endorsement, lack of institutional investment, if they will guzump all the timelines to push for a DMOAD label before NDA whilst there is absolutely no clear pathway.

    I could say I told you so, so I will.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.